Superior pathological complete response to neo-adjuvant chemotherapy in breast cancer amongst women with BRCA1/2 mutations.

被引：0
|
作者：
Paluch-Shimon, S. [1 ]
Papa, M. Z. [1 ]
Friedman, E. [1 ]
Shabtai, M. [1 ]
Yosepovich, A. [1 ]
Modiano, T. [1 ]
Goldfarb, A. [1 ]
Catane, R. [1 ]
Kaufman, B. [1 ]
机构：
[1] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
来源：
CANCER RESEARCH | 2009年 / 69卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：331S / 331S
页数：1
相关论文
共 50 条
  • [21] Predictive markers for pathological complete response (pCR) after neo-adjuvant chemotherapy in HER2-positive breast carcinoma
    Bockstal, Mieke R. Van
    Dano, Helene
    Benhaddi, Naima
    Dubois, Dominique
    Vanderveken, Jonathan
    Van Marcke, Cedric
    Vandermeulen, Ad
    Duhoux, Francois P.
    Vernaeve, Hilde
    Berliere, Martine
    Galant, Christine
    HISTOLOGY AND HISTOPATHOLOGY, 2024, 39 (02) : 153 - 164
  • [22] Uptake of free BRCA1/2 testing in women at risk for BRCA1/2 germline mutations.
    Shannon, KM
    Lubratovich, ML
    Finkelstein, D
    Goggins, W
    Haber, DA
    Seiden, MV
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A322 - A322
  • [23] Apparent diffusion coefficient: Potential biomarker for complete response after neo-adjuvant chemotherapy in breast cancer
    Grana-Lopez, Lucia
    Herranz, Michel
    Macineira, Fiz Andres
    Villares, Angeles
    Vazquez-Caruncho, Manuel
    BREAST JOURNAL, 2020, 26 (02): : 306 - 308
  • [24] CAN ER/PR AND HER2 RECEPTOR STATUS PREDICT COMPLETE PATHOLOGICAL RESPONSE AFTER NEO-ADJUVANT CHEMOTHERAPY IN PATIENTS WITH BREAST CANCER?
    Sircar, T.
    Athwal, R.
    Brown, H.
    Dea, D.
    Hoar, F.
    EJC SUPPLEMENTS, 2010, 8 (06): : 11 - 11
  • [25] Identification of breast-ovarian cancer families without BRCA1 or BRCA2 mutations.
    Unger, M
    Nathanson, KL
    Antin-Ozerkis, D
    Martin, AM
    Shih, HA
    Calzone, KA
    Ward, T
    Mazoyer, S
    Rebbeck, T
    Weber, BL
    AMERICAN JOURNAL OF HUMAN GENETICS, 1999, 65 (04) : A328 - A328
  • [26] Prediction and assessment of response to neo-adjuvant chemotherapy in breast cancer: The responsibilities of breast pathologists
    Masood, Shahla
    BREAST JOURNAL, 2021, 27 (08): : 629 - 630
  • [27] Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
    Kim, SJ
    Kim, SK
    Lee, ES
    Ro, J
    Kang, SH
    ANNALS OF ONCOLOGY, 2004, 15 (09) : 1352 - 1357
  • [28] BRCA1 mutations in young women with breast cancer
    Struewing, JP
    Tarone, RE
    Brody, LC
    Li, FP
    Boice, JD
    LANCET, 1996, 347 (9013): : 1493 - 1493
  • [29] Homologous recombination deficiency in breast cancer and association with response to neo-adjuvant chemotherapy
    Lips, E. H.
    Mulder, L.
    Hannemann, J.
    Peeters, M. J. Vrancken
    van de Vijver, M. J.
    Wesseling, J.
    Nederlof, P. M.
    Rodenhuis, S.
    EJC SUPPLEMENTS, 2010, 8 (03): : 60 - 61
  • [30] Long-term significance (15 years) of pathological complete response after dose-dense neo-adjuvant chemotherapy in breast cancer
    Wang-Lopez, Qian
    Abrial, Catherine
    Planchat, Eloise
    Mouret-Reynier, Marie-Ange
    Cure, Herve
    Gimbergues, Pierre
    Dubray-Longeras, Pascale
    Gallon-Bernard, Dominique J.
    Kwiatkowski, Fabrice
    Chollet, Philippe J.
    Durando, Xavier
    CANCER RESEARCH, 2012, 72
12345